Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes

Trial Profile

Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Aldesleukin (Primary)
  • Indications Acute coronary syndromes; Ischaemic heart disorders; Myocardial infarction
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LILACS
  • Most Recent Events

    • 28 Sep 2017 Protocol has been amended to change in primary endpoint and addition of Part B inclusion Exclusion .
    • 20 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top